Your session is about to expire
← Back to Search
Biomaterial
Collagen Matrix + Growth Factor for Implant Complications
N/A
Recruiting
Led By Lorenzo Tavelli, DDS, MS
Research Sponsored by Harvard Medical School (HMS and HSDM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3, 6 and 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial compares two methods for treating issues around dental implants, CTG or a collagen matrix+growth factor.
Who is the study for?
This trial is for adults over 18 who have good oral hygiene and are in general good health. They should have a single dental implant in the front of their mouth with peri-implant soft tissue dehiscences, which they want to treat.
What is being tested?
The study compares two treatments for aesthetic issues around dental implants: one uses a collagen matrix with growth factor (rhPDGF-BB), and the other uses tissue from the patient's own body.
What are the potential side effects?
Potential side effects may include discomfort at the graft site, swelling, infection risk, and possible allergic reactions to collagen or rhPDGF-BB.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3, 6 and 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3, 6 and 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Soft tissue dehiscence reduction
Secondary study objectives
3D Volumetric changes
Complete peri-implant soft tissue dehiscence (PSTD) coverage
Mucosal thickness changes
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Collagen matrix + rhPDGF-BBExperimental Treatment1 Intervention
Xenogeneic cross-linked collagen matrix + recombinant human platelet-derived growth factor-BB
Group II: Connective tissue graftActive Control1 Intervention
Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized
Find a Location
Who is running the clinical trial?
Harvard Medical School (HMS and HSDM)Lead Sponsor
204 Previous Clinical Trials
1,316,657 Total Patients Enrolled
1 Trials studying Implant Complication
28 Patients Enrolled for Implant Complication
Lorenzo Tavelli, DDS, MSPrincipal InvestigatorHarvard School of Dental Medicine, Boston, USA
2 Previous Clinical Trials
58 Total Patients Enrolled
1 Trials studying Implant Complication
28 Patients Enrolled for Implant Complication
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I had soft tissue grafting at the implant site with problems in the last 6 months.I cannot undergo surgery due to health risks.My gums and overall health are good.I can take care of my teeth and mouth properly.I have untreated gum disease.I have untreated gum disease around my dental implant.I have a condition like diabetes or HIV that could affect wound healing.
Research Study Groups:
This trial has the following groups:- Group 1: Connective tissue graft
- Group 2: Collagen matrix + rhPDGF-BB
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.